Introduction: Locoregionally recurrent rectal cancer (LRRC) remains one of the most challenging scenarios in colorectal oncology. Recurrence within the pelvis is often associated with significant morbidity, impaired quality of life, and limited treatment options.
Introduction:
Locoregionally recurrent rectal cancer (LRRC) remains one of the most challenging scenarios in colorectal oncology. Recurrence within the pelvis is often associated with significant morbidity, impaired quality of life, and limited treatment options. Advances in surgery, radiation therapy, systemic therapy, and imaging have improved outcomes; however, optimal management requires careful integration of multiple treatment modalities and expertise across specialties.
Problem Statement:
The management of LRRC is highly individualized and influenced by prior treatments, anatomical location of recurrence, extent of disease, and resectability. Given the complexity of these cases, clinicians require evidence-based guidance to determine the most appropriate combination and sequencing of therapies while maximizing the chance of durable disease control.
Summary:
This American Radium Society Appropriate Use Criteria review provides comprehensive multidisciplinary guidance for the management of locoregionally recurrent rectal cancer. Drawing upon evidence from more than 100 studies and expert consensus, the document reinforces that achieving a margin-negative (R0) surgical resection remains the most important determinant of long-term survival and local disease control. The guidelines emphasize that successful surgery often depends on appropriate use of preoperative therapies, including systemic chemotherapy, radiation therapy, or combined-modality approaches, which can facilitate tumor downsizing and improve resectability. Treatment decisions should be tailored according to prior treatment exposure, recurrence location, and disease extent, highlighting the importance of individualized care planning. The review strongly advocates for management within experienced multidisciplinary teams involving colorectal surgeons, radiation oncologists, medical oncologists, radiologists, and gastroenterologists. While the recommendations do not fundamentally alter current treatment paradigms, they provide important validation of contemporary practice and underscore the continued value of combined-modality therapy in improving outcomes. Overall, the guidance supports a personalized, multidisciplinary strategy focused on maximizing the likelihood of complete resection while integrating systemic and local therapies to optimize survival and local control in patients with recurrent rectal cancer.
Introduction: Circulating tumor DNA (ctDNA) has emerged as a promising noninvasive biomarker for monitoring treatment response and residual disease in solid tumors. However, its prognostic value during neoadjuvant chemotherapy (NAC) for localized pancreatic ductal adenocarcinoma...
Introduction: Aspirin is one of the few interventions proven to reduce colorectal and other Lynch syndrome–associated cancers. The earlier CaPP2 trial established 600 mg daily aspirin as an effective chemopreventive strategy, but concerns regarding long-term...
Introduction: The TOPAZ-1 trial established durvalumab combined with gemcitabine and cisplatin (GemCis) as the first immunotherapy-based first-line standard of care for advanced biliary tract cancer (BTC). However, long-term survival outcomes and durability of benefit beyond...
Introduction: Somatostatin receptor (SSTR) PET/CT has become indispensable for diagnosing, staging, and monitoring neuroendocrine tumors (NETs). However, until now, there has been no standardized method for assessing treatment response using SSTR PET imaging. This international...
Introduction: Staging laparoscopy (SL) is recommended for patients with locally advanced gastric cancer to detect occult peritoneal metastases before curative treatment. However, its real-world utilization across Europe remains uncertain. This large GASTRODATA study evaluated the...
Introduction: Neoadjuvant immune checkpoint inhibitors have transformed the management of mismatch repair-deficient (dMMR) or microsatellite instability-high (MSI-H) locally advanced colorectal cancer, achieving unprecedented pathological response rates. Experimental evidence suggests that cyclooxygenase-2 (COX-2) inhibition may enhance...
We are pioneers in clinical intelligence, dedicated to helping gastroenterologists harness the power of artificial intelligence to drive precision, efficiency, and patient growth.